Loading
IKBKB (Inhibitor of nuclear factor kappa-B kinase subunit beta) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma, Skin cancer, Breast cancer and 2 more.
Serine kinase that plays an essential role in the NF-kappa-B signalling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as a part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation. Phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues.
Open Targets scores its association with cancer at 0.70 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.00, somatic mutation 0.90, clinical 0.08). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Plasma Cell Myeloma.
In plain words · IKBKB (Inhibitor of nuclear factor kappa-B kinase subunit beta) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma, Skin cancer, Breast cancer and 2 more.
IKBKB (Inhibitor of nuclear factor kappa-B kinase subunit beta) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma, Skin cancer, Breast cancer and 2 more.
Serine kinase that plays an essential role in the NF-kappa-B signalling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses.
No product in this corpus aims at IKBKB yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA IKBKB: RNA low tissue specificity; no normal tissue stained high; highest cancer staining endometrial cancer (9 of 11 high). Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Skin cancer (all types), Breast cancer (all types), Lung cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt O14920; IntOGen IKBKB; Human Protein Atlas IKBKB tissue; Open Targets ENSG00000104365 associations
First described 1997. Earliest sequence paper UniProt cites for the protein: Mercurio et al, Science, 1997, "IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation". Source.
Sources: HGNC HGNC:5960 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O14920 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000104365 (association with cancer (MONDO_0004992) 0.70; per-cancer scores at or above 0.5: melanoma 0.57, skin cancer 0.56, breast cancer 0.54, lung cancer 0.53 (GraphQL API, CC0)); IntOGen IKBKB (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Serine kinase that plays an essential role in the NF-kappa-B signalling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as a part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation. Phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. In addition to the NF-kappa-B inhibitors, phosphorylates several other components of the signalling pathway including NEMO/IKBKG, NF-kappa-B subunits RELA and NFKB1, as well as IKK-related kinases TBK1 and IKBKE. Location: Cytoplasm; Nucleus; Membrane raft (UniProt). Locus 8p11.21 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high; medium in Appendix, Bone marrow, Breast, Cerebral cortex, Cervix, Colon and more.
Medium only: carcinoid, liver cancer, lung cancer, pancreatic cancer.
HPA IKBKB tissue · HPA IKBKB pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"IKBKB" OR ABSTRACT:"IKBKB" OR TITLE:"inhibitor of nuclear factor kappa B kinase subunit beta" OR ABSTRACT:"inhibitor of nuclear factor kappa B kinase subunit beta" OR TITLE:"Inhibitor of nuclear factor kappa-B kinase subunit beta" OR ABSTRACT:"Inhibitor of nuclear factor kappa-B kinase subunit beta" OR TITLE:"IKK2" OR ABSTRACT:"IKK2" OR TITLE:"NFKBIKB" OR ABSTRACT:"NFKBIKB" OR TITLE:"IKK-beta" OR ABSTRACT:"IKK-beta") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IKBKB, not a curated reading list.